Buerger's Disease Clinical Trial Pipeline Gains Momentum: 3+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Image: http://www.abnewswire.com/pressreleases/wp-content/uploads/2026/09/2026
The Buerger's Disease clinical trial analysis report delivers important insights into ongoing research of 3+ pipeline Buerger's Disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
(Albany, US) , September 20, 2026 - DelveInsight's " Buerger's Disease Pipeline Insight, 2026 " report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Buerger's Disease pipeline landscape. It covers the Buerger's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Buerger's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Buerger's Disease Treatment Landscape @ https://www.delveinsight.com/report-store/buergers-disease-pipeline-insight [https://www.delveinsight.com/sample-request/buergers-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr]

Key Takeaways from the Buerger's Disease Pipeline Report

*
DelveInsight's Buerger's Disease pipeline report depicts a focused space with 3+ active players working to develop 3+ pipeline therapies for Buerger's Disease treatment.

*
The leading Buerger's Disease Companies include K-STEMCELL, Antidote Therapeutics, Caladrius Biosciences, and others.

*
Promising Buerger's Disease Pipeline Therapies such as Mesenchymal stem cell therapy (VascoStem) and ATI-1013, and others.

*
The companies which have their Buerger's Disease drug candidates in the most advanced stage, i.e. Phase III, include Caladrius Biosciences.

Gain in-depth knowledge of key Buerger's Disease clinical trials, emerging drugs, and market opportunities @ Buerger's Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/buergers-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr]

Buerger's Disease Overview

Buerger's disease, also known as Thromboangiitis obliterans, is a rare vascular disease in which blood vessels of the hands and feet become blocked. Affected individuals may notice pain as an early finding, or coldness in the fingers; later findings include fingers or toes that appear pale, red, or bluish, sudden severe pain in the hands and feet, skin ulcers, gangrene, and, ultimately, amputation. Diagnosis of the vessel blockage can be made through plethysmography, Doppler ultrasound of the extremity, or catheter-based x-ray arteriogram, and blood tests may be performed to rule out other causes of vasculitis or blood vessel occlusion.

The goal of treatment for Buerger's disease is to control symptoms and prevent the disease from worsening. Total tobacco cessation - including smoking, secondhand smoke, and nicotine replacement therapy - is the only treatment shown to improve symptoms and reduce the risk of amputation, provided it occurs before the onset of gangrene or tissue loss. Additional medication options include calcium channel blockers, anticoagulants, thrombolytics, and prostaglandin analogs, alongside interventions such as sympathectomy, adrenalectomy, spinal cord stimulators, and omental transfers.

Buerger's Disease Emerging Drugs Profile

*
Mesenchymal Stem Cell Therapy (VascoStem): K-STEMCELL This mesenchymal stem cell therapy is a drug candidate that improves or treats ischemic ulcers and other complications caused by Buerger's disease. Once injected, VascoStem indirectly vascularizes tissue through the vascular endothelial growth factor (VEGF) it secretes and directly restores damaged tissue. The molecule is in the Phase I/II clinical trial stage for the treatment of Buerger's Disease. VascoStem was awarded rare pharmaceutical product designation by the U.S. Food and Drug Administration (FDA) in May 2016 as a treatment for Buerger's disease, based on the results of Phase I/II clinical trials in Korea, and the European Medicines Agency (EMA) granted it orphan drug designation in March 2017.

*
ATI-1013: Antidote Therapeutics ATI-1013 is a human monoclonal antibody that sequesters nicotine in the blood, discovered by harnessing the human immune system's capacity to generate high-affinity antibodies to external antigens. The nicotine-specific mAb program has been supported by an $8.5 million Strategic Alliance grant award from the National Institute on Drug Abuse Division of Therapeutics and Medical Consequences at the National Institutes of Health, which led to the discovery and development of ATI-1013. The drug has also received Orphan Drug Designation from the FDA.

The Buerger's Disease Pipeline Report Provides Insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Buerger's Disease, with aggregate therapies developed by each company.

*
It assesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for Buerger's Disease treatment.

*
Buerger's Disease Companies are involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.

*
Buerger's Disease drugs under development are categorized based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecule type.

*
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, mergers and acquisitions, and funding for future advancement of the Buerger's Disease market.

Uncover critical updates on therapeutic innovations and their potential impact on patients @ Buerger's Disease Unmet Needs [https://www.delveinsight.com/sample-request/buergers-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr]

Buerger's Disease Companies

K-STEMCELL, Antidote Therapeutics, Caladrius Biosciences, and others.

Buerger's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

*
Oral

*
Parenteral

*
Intravitreal

*
Subretinal

*
Topical

Buerger's Disease Products have been categorized under various Molecule types such as:

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Transform your understanding of the Buerger's Disease Pipeline! @ Buerger's Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/buergers-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr]

Scope of the Buerger's Disease Pipeline Report

*
Coverage- Global

*
Buerger's Disease Companies- K-STEMCELL, Antidote Therapeutics, Caladrius Biosciences and others.

*
Buerger's Disease Pipeline Therapies- Mesenchymal stem cell therapy (VascoStem), ATI-1013 and others.

*
Buerger's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

*
Buerger's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Buerger's Disease Pipeline Analysis Today! @ Buerger's Disease Drugs and Companies [https://www.delveinsight.com/sample-request/buergers-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr]

Table of Contents

*
Introduction

*
Executive Summary

*
Buerger's Disease: Overview

*
Comparative Analysis

*
Late Stage Products (Phase III)

*
Mid Stage Products (Phase II)

*
Early Stage Products (Phase I/II)

*
Preclinical/Discovery Stage Products

*
Inactive Products

*
Buerger's Disease Key Companies

*
Buerger's Disease Key Products

*
Buerger's Disease Unmet Needs

*
Buerger's Disease Market Drivers and Barriers

*
Buerger's Disease Future Perspectives and Conclusion

*
Buerger's Disease Analyst Views

*
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email [http://www.abnewswire.com/email_contact_us.php?pr=buergers-disease-clinical-trial-pipeline-gains-momentum-3-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight]
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/buergers-disease-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.